Kaneda-Nakashima, K.; Shirakami, Y.; Hisada, K.; Feng, S.; Kadonaga, Y.; Ooe, K.; Watabe, T.; Manabe, Y.; Shimoyama, A.; Murakami, M.;
et al. Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211. Int. J. Mol. Sci. 2024, 25, 12386.
https://doi.org/10.3390/ijms252212386
AMA Style
Kaneda-Nakashima K, Shirakami Y, Hisada K, Feng S, Kadonaga Y, Ooe K, Watabe T, Manabe Y, Shimoyama A, Murakami M,
et al. Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211. International Journal of Molecular Sciences. 2024; 25(22):12386.
https://doi.org/10.3390/ijms252212386
Chicago/Turabian Style
Kaneda-Nakashima, Kazuko, Yoshifumi Shirakami, Kentaro Hisada, Sifan Feng, Yuichiro Kadonaga, Kazuhiro Ooe, Tadashi Watabe, Yoshiyuki Manabe, Atsushi Shimoyama, Masashi Murakami,
and et al. 2024. "Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211" International Journal of Molecular Sciences 25, no. 22: 12386.
https://doi.org/10.3390/ijms252212386
APA Style
Kaneda-Nakashima, K., Shirakami, Y., Hisada, K., Feng, S., Kadonaga, Y., Ooe, K., Watabe, T., Manabe, Y., Shimoyama, A., Murakami, M., Toyoshima, A., Haba, H., Kanai, Y., & Fukase, K.
(2024). Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211. International Journal of Molecular Sciences, 25(22), 12386.
https://doi.org/10.3390/ijms252212386